Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score N/A
- Piotroski Score N/A
- Grade Hold
- Symbol (TRIL)
- Company Trillium Therapeutics Inc.
- Price $18.44
- Changes Percentage (0%)
- Change -$0
- Day Low $17.83
- Day High $18.49
- Year High $20.96
Trillium Therapeutics Inc., a clinical stage immuno-oncology company, develops therapies for the treatment of cancer. The company's lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced relapsed or refractory hematologic malignancies, and solid tumors and mycosis fungoides. Its product candidates also include TTI-622 that is in Phase I clinical trial of immunoglobulin G4 SIRPaFc protein; and TTI-10001, a small molecule stimulator of interferon genes agonist that senses cytosolic DNA for promoting tumor immunity, which is in the discovery Phase. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was founded in 2004 is headquartered in Mississauga, Canada.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/12/2021
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Buy
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $0.00
- Trailing P/E Ratio 0
- Forward P/E Ratio 0
- P/E Growth 0
- Net Income $-59,346,000
Income Statement
Quarterly
Annual
Latest News of TRIL
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
The Mavericks of Metals Are Back, Rocking a $15 Trillion Market
In 2002, the metals industry faced turmoil as a US warehouse started charging fees for cargo storage, sparking complaints from traders....
By Yahoo! Finance | 22 hours ago -
Jim Cramer on NVIDIA Corporation (NASDAQ:NVDA): "A $10 Trillion Stock"
Insider Monkey published Jim Cramer's top 11 stocks for Q4, with NVIDIA ranking 1st. Cramer advises taking profits during stock rallies. NVIDIA's growth potential in data center market is promising de...
By Yahoo! Finance | 1 day ago -
Prediction: This AI Stock Will Be the Next Company to Reach a Trillion-Dollar Market Cap
Taiwan Semiconductor Manufacturing (TSM) is poised to be the next company to hit a $1 trillion market cap due to its dominance in producing advanced semiconductors for AI applications. With a strong e...
By Yahoo! Finance | 2 days ago
